Parasitological Cure of Chagas Disease: Is it Possible? Is it Relevant?

Memorias do Instituto Oswaldo Cruz

Volumn 94, Issue SUPPL. 1, 1999, Pages 349-355

  Urbina, Julio A ^a  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

Author keywords

Chagas disease; Parasitology; Trypanosoma cruzi

Indexed keywords

TRYPANOSOMA; TRYPANOSOMA CRUZI;

ANTITRYPANOSOMAL AGENT;

ACUTE DISEASE; ANIMAL; CHAGAS DISEASE; CHRONIC DISEASE; DRUG EFFECT; HUMAN; PARASITOLOGY; PHYSIOLOGY; REVIEW; TRYPANOSOMA CRUZI;

ACUTE DISEASE; ANIMALS; CHAGAS DISEASE; CHRONIC DISEASE; HUMANS; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 0033256630     PISSN: 00740276     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0074-02761999000700068     Document Type: Article

References (78)

1. Andrade ALS, Zicker F 1997. Should benznidazole be used in chronic Chagas disease? Lancet 349: 653.
2. Andrade ALS, Zicker F, Oliveira RM, Silva SA, Luquetti A, Travassos LR, Almeida IC, Andrade SS, Andrade JG, Martelli CMT 1996. Randomised trial of efficacy of benznidazole in treatment of early Trypanossoma cruzi infection. Lancet 348: 1407-1413.
3. Andrade SG, Stocker-Guerret S, Pimentel AS, Grimaud JA 1991. Reversibility of cardiac fibrosis in mice chronically infected with Trypanosoma cruzi, under specific chemotherapy. Mem Inst Oswaldo Cruz 86: 187-200.
4. Apt W, Aguilera X, Arribada A, Pérez C, Miranda C, Sánchez G, Zulantay I, Cortés P, Rodriguez J, Juri D 1998. Treatment of chronic Chagas disease with itraconazole and allopurinol. Am J Trop Med Hyg 59: 133-138.
5. Avila JL, Avila A 1981. Trypanosoma cruzi: effect of allopurinol in the treatment of mice with experimental acute Chagas disease. Exp Parasitol 51: 204-208.
6. Avila JL, Avila A, Casanova J 1981. Effects of allopurinol on different strains of Trypanosoma cruzi. Am J Trop Med Hyg 39: 769-774.
7. Beach DH, Goad LJ, Holz Jr GG 1986. Effects of ketoconazole on sterol biosynthesis by Trypanosoma cruzi. Biochem Biophys Rex Comm 135: 851-856.
8. Bestetti RB 1996. Role of parasites in the pathogenesis of Chagas cardiomyopathy. Lancet 347: 913-914.
9. Bestetti RB 1997. Should benznidazole be used in chronic Chagas disease? Lancet 349: 653.
10. Bond CS, Zhang Y, Berriman M, Cunningham ML, Fairlamb AH, Hunter WN 1999. Crystal structure of Trypanosoma cruzi trypanothione reductase in complex with trypanothione and the structure-based discovery of new natural product inhibitors. Structure 7: 81-89.
11. Brandariz S, Schijman A, Vigliano C, Arteman P, Viotti R, Beldjord C, Levin MJ 1995. Detection of parasite DNA in Chagas' heart disease. Lancet 346: 1370-1371.
12. Brandariz S, Schijman A, Vigliano C, Viotti R, Levin MJ 1996. Role of parasites in the pathogenesis of Chagas' cardiomyopathy. Lancet 347: 914.
13. Brener Z, Gazzinelli RT 1997. Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas disease. Int Arch Allergy Immunol 114: 103-110.
14. Brener Z, Cançado JR, Galvão LM, da Luz ZMP, Filardi LdS, Pereira MES, Santos LMT, Cançado CB 1993. An experimental and clinical assay with ketoconazole in the treatment of Chagas disease. Mem Inst Oswaldo Cruz 88: 149-153.
15. i-dependent enzyme in trypanosmatids: Pyruvate, phosphate dikinase. Proc Natl Acad Sci USA 95: 7963-7968.
16. Clemons KV, Hanson LH, Stevens DA 1993. Activities of the triazole D0870 in vitro and against murine blastomycosis. Antimicrob Agents Chemother 37: 1177-1179.
17. Croft SL, Urbina JA, Brun R 1997. Chemotherapy of human leishmaniasis and trypanosomiasis, p. 245-257. In G Hide, JC Mottram, GH Coombs & PH Holmes, Trypanomiasis and Leishmaniasis, CAB International, London.
18. Cunha-Neto E, Duranti M, Gruber A, Zingales B, De Messias I, Stolf N, Bellotti G, Patarroyo ME, Kalil J 1995. Autoinmunity in Chagas disease cardiopathy: Biological relevance of a cardiac myosin-specific epitope crossreactive to an inmunodominant Trypanosoma cruzi antigen. Proc Natl Acad Sci USA 92: 3541-3545.
19. de Castro Solange L 1993. The challenge of Chagas disease chemotherapy: an update of drugs assayed against Trypansoma cruzi. Acta Tropica 53: 83-98.
20. De Wit S, O'Doherty E, Smith RP, Yates R, Clumeck N 1995. Pharmacokinetics of two multiple dosing regimens of D0870 in HIV positive patients: A phase I study. ICAAC Abstracts 35: F97.
21. Docampo R 1990. Sensitivity of parasites to free radical damage by antiparasitic drugs. Chem-Biol Interactions 73: 1-27.
22. Docampo R, Moreno SNJ 1986. Free radical metabolism of antiparasitic agents. Federation Proc 45: 2471-2476.
23. Docampo R, Schmuñis GA 1997. Sterol biosynthesis inhibitors: potential chemotherapeutics against Chagas disease. Parasitol Today 13: 129-130.
24. Docampo R, Moreno SNJ, Turrens JF, Katzin AM, Gonzales-Cappa SM, Stoppani AOM 1981. Biochemical and ultrastructural alterations produced by miconazole and econazole in Trypanosoma cruzi. Mol Biochem Parasitol 3: 169-180.
25. 2+ storage in acidocalcisomes of Trypanosama cruzi. Biochem J 310: 1005-1012.
26. Dumas C, Oulette M, Tovar J, Cunningham ML, Fairlamb AH, Tamar S, Olivier M, Papadopoulou B 1997. Disruption of the trypanothione reductase gene in Leishmania decreases its ability to survive oxidative stress in macrophages. EMBO J 16: 2590-2598.
27. Fairlamb AH, Cerami A 1992. Metabolism and functions of trypanothione in kinetoplastida. Ann Rev Microbiol 46: 695-729.
28. Filardi LS, Brener Z 1987. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used in Chagas disease. Trans R Soc Trop Med Hyg 81: 755-759.
29. Gianella A 1994. Alopurinol en la enfermedad de Chagas crónica. Reunião Anual de Pesquisa Aplicada en Doença de Chagas 10: 89.
30. Girijavallabhan VM, Saksena AK, Lovey RG, Bennet F, Pike RE, Wang H, Pinto P, Lin YT, Patel N, Ganguly AK 1995. SCH 56592, a novel broad spectrum antifungal agent. ICAAC Abstracts 35: F61.
31. Goad LJ, Berens RL, Marr JJ, Beach DH, Holz Jr GG 1989. The activity of ketoconazole and other azoles against Trypanosoma cruzi: biochemistry and chemotherapeutic action in vitro. Mol Biochem Parasitol 32: 179-190.
32. Jones EM, Colley DG, Tosies S, Reis Lopes E, Vnencak-Jones CL, McCurley TL 1993. Amplification of a Trypanosoma cruzi DNA sequence from inflamatory lesions in human chagasic cardiomyopathy. Am J Trop Med Hyg 48: 348-357.
33. Kalil J, Cunha-Neto E 1996. Autoimmunity in Chagas disease cardiomyopathy: fullfilling the criteria at last? Parasitol Today 12: 396-399.
34. Kaplan D, Ferrari I, Lopez-Bergami P, Mahler E, Levitus G, Chiale P, Hoebeke J, Van Regenmortel MHV, Levin MJ 1997. Antibodies to ribosomal P proteins of Trypanosoma cruzi in Chagas disease possess functional autoreactivity with heart tissue and differ from anti-P autoantibodies in lupus. Proc Natl Acad Sci USA 94: 10301-10306.
35. Kelly JM, Taylor MC, Smith K, Hunter KJ, Fairlamb, AH 1993. Phenotype of recombinant Leishmania donovani and Trypanosoma cruzi which over-express trypanothione reductase-sensitivity towards agents that are thought to induce oxidative stress. European J Bioch 218: 29-37.
36. Laughlin M, Pai S, Menon S, Nomeir A, Colucci R, Affrime M, Kosoglou T 1997. SCH 56592: rising multiple-dose safety, tolerance, and pharmacokinetic evaluation in healthy volunteers. ICAAC Abstracts 37: A87.
37. Levin MJ 1996. In chronic Chagas heart disease, don't forget the parasite. Parasitol Today 12: 415-416.
38. Licata AA 1997. Bisphosphonate therapy. Am J Med Sci 313: 17-22.
39. Liendo A, Lazardi K, Urbina JA 1998. Antiproliferative effects and mechanism of action of D0870 and its S(-) enantiomer against Trypanosoma cruzi. J Antimicrob Chemother 41: 197-205.
40. 2+ pool content and signaling and expression of a calcium pump are linked to virulence in Leishmania mexicana amazonensis amastigotes. J Biol Chem 272: 9464-9473.
41. Lyr H 1995. Modern Selective Fungicides, 2nd ed., Gustav Fisher Verlag, Jena.
42. Maldonado RA, Molina J, Payares G, Urbina JA 1993. Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chagas disease. Antimicrob Agents Chemother 37: 1353-1359.
43. McCabe RE 1988. Failure of ketoconazole to cure chronic murine Chagas disease. J Infect Dis 158: 1408-1409.
44. Mercer EI 1993. Inhibitors of sterol biosynthesis and their applications. Prog Lipid Res 32: 357-416.
45. Molina J, Araujo MSS, Pereira MES, Brener Z, Urbina JA 1997. Activity of the bis-triazole D0870 against drug-resistant Trypanosoma cruzi strains. ICAAC Abstracts 37: B41b.
46. Moreira AAB, DeSouza HBWT, Amato Neto V, Matsubara L, Pinto PLS, Tolezano JE, Nunes EV, Okumura M 1992. Avaliacão da atividade terapêutica do itraconazol nas infecçoes crônicas, experimental e humana, pelo Trypanosoma cruzi. Rev Inst Med Trop São Paulo 34: 177-180.
47. Moreno SNJ, Zhong L 1996. Acidocalcisomes in Toxoplasma gondii tachyzoites. Biochem J 313: 655-659.
48. Nomeir A, Kumari P, Hilbert MJ, Loebenberg D, Cacciapuoti A, Menzel Jr J, Moss Jr E, Hare R, Miller GH, Cayen MN, Lin CC 1995. Comparative pharmacokinetics of a new triazole antifungal agent, SCH 56592, in mice, rats, rabbits, dogs and cynomolgus monkeys. ICAAC Abstracts 35: F68.
49. Quintas LEM, Siqueira-Batista R 1996. Immunologia, p. 53-74. In R Siqueira-Batista, AD Corrêa & DW Huggins, Molestia de Chagas, Cultura Médica, Rio de Janeiro.
50. Quintas LEM, de Castro SL, Urbina JA, Borba-Santos JA, Pinto CN, Siqueira-Batista R, Miranda Filho N 1996. Tratamento da doença de Chagas, p. 125-170. In R Siqueira-Batista, AD Corrêa & DW Higgins (eds), Molestia de Chagas, Cultura Médica, Rio de Janeiro.
51. Rassi A, Luquetti AO 1992. Therapy of chagas Disease, p. 237-247. In S Wendel, Z Brener, ME Camargo & A Rassi, Chagas Disease (American Trypanosomiasis): Its Impact on Transfusion and Clinical Medicine, ISBT, São Paulo.
52. Ribeiro dos Santos R, Rossi MA, Laus JL, Santana Silva J, Savino W, Mengel J 1992. Anti-CD4 abrogates rejection and reestablishes long-term tolerance to syngeneic newborn hearts grafted in mice chronically infected with Trypanosoma cruzi. J Exp Med 175:29-39.
53. Rodan GA 1998. Mechanisms of action of bisphosphonates. Ann Rev Pharmacol Toxicol 38: 375-388.
54. Rogers MJ, Watts DJ, Russell RGG 1997. Overview of bisphosphonates. Cancer 80: 1652-1660.
55. Rosenbaum MB, Chiale PA, Schejtman D, Levin MJ, Elizari MV 1994. Antibodies to beta-adrenergic receptors disclosing agonist-like properties in idiopathic dilated cardiomyopathy and Chagas' heart disease. J Cardiovasc Electrophysiol 5: 367-375.
56. Ryder NS, Mieth H 1992. Allylamine antifungal drugs. Curr Top Med Mycol 4: 158-188.
57. Sandler M, Smith HJ 1994. Design of Enzyme Inhibitors as Drugs, Vol. 2, Oxford University Press, Oxford, New York.
58. Scott DA, DeSouza W, Benchimol M, Zhong L, Lu H-G, Moreno SNJ, Docampo R 1998. Presence of a plant-like proton-pumping pyrophosphatase in acidocalcisomes of Trypanosoma cruzi. J Biol Chem 273: 22151-22158.
59. Tarleton RL, Zhang L, Downs MO 1997. "Autoinmune rejection" of neonatal heart transplants in experimental Chagas disease is a parasite-specific response to infected host tissue. Proc Natl Acad Sci USA 94: 3932-3937.
60. Temperton NJ, Wilkinson SR, Meyer DJ, Kelly JM 1998. Overexpression of superoxide dismutase in Trypanosoma cruzi results in increased sensitivity to the trypanocydal agents gentian violet and benznidazole. Mol Biochem Parasitol 96: 167-176.
61. Tovar J, Cunningham ML, Smith AC, Croft SL, Fairlamb AH 1998a. Down-regulation of Leishmania donovani trypanothione reductase by heterologous expression of a trans-dominant homologue: effect on parasite intracellular survival. Proc Natl Acad Sci USA 95: 5311-5316.
62. Tovar J, Wilkinson S, Mottram JC, Fairlamb AH 1998b. Evidence that trypanothione reductase is an essential enzyme in Leishmania by targeted relacement of the tryA gene locus. Mol Microbiol 29: 653-660.
63. Urbina JA 1997. Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites. Parasitol 117: S91-S99.
64. Urbina JA 1999. Chemotherapy of Chagas disease: the how and the why. J Mol Med 77: 332-338.
65. Urbina JA, Lazardi K, Aguirre T, Piras MM, Piras R 1988. Antiproliferative synergism of the allylamine SF-86327 and ketoconazole on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother 32: 1237-1242.
66. Urbina JA, Lazardi K, Marchan E, Visbal G, Aguirre T, Piras MM, Piras R, Maldonado RA, Payares G, DeSouza W 1993. Mevinolin (lovastatin) potentiates the antiproliferative effects of ketoconazole and terbinafine against Trypanosoma (Schizotrypanum) cruzi: in vivo and in vitro studies. Antimicrob Agents Chemother 37: 580-591.
67. Urbina JA, Moreno B, Vierkotter S, Oldfield E, Moreno SNJ, Bailey BN, Yan W, Scott DA, Docampo R 1999. Pyrophosphate is the most abundant high-energy phosphate compound in trypanosmatid and apicomplexan parasites and non-metabolizable analogs inhibit their proliferation in vitro and in vivo. Mem Inst Oswaldo Cruz 93 (Suppl. II): 72.
68. Urbina JA, Payares G, Molina J, Sanoja C, Liendo A, Lazardi K, Piras MM, Piras R, Perez N, Wincker P, Ryley JF 1996a. Cure of short- and long-term experimental Chagas disease using D0870. Science 273: 969-971.
69. Urbina JA, Payares G, Contreras LM, Liendo A, Sanoja C, Molina J, Piras MM, Piras R, Perez N, Wincker P, Loebenberg D 1998. Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob Agents Chemother 42: 1771-1777.
70. 24(25)-sterol methyl transferase inhibitors and their combinations with ketoconazole. Mol Biochem Parasitol 73: 199-210.
71. 24(25) sterol methyl transferase inhibitors on Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Chemotherapy 42: 294-307.
72. Vanden Bossche H 1995. Chemotherapy of human fungal infections, p. 431-484. In H Lyr, Modern Selective Fungicides. Properties, Applications, Mechanism of Action, Gustav Fisher Verlag, Jena.
73. 2+ release from acidocalcisomes of Trypanosoma brucei. Biochem J 315: 265-270.
74. + exchange in acidic vacuoles of Trypanosoma brucei. Biochem J 304: 227-233.
75. Viotti R, Vigliano C, Armenti H, Segura E 1994. Treatment of chronic Chagas disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J 127: 151-162.
76. World Bank 1993. World Development Report 1993/ 1994: Investing in Health , Oxford University Press, Oxford.
77. World Health Organization 1995. Tropical Disease Research, Twelfth Programme Report, p. 129-133. WHO, Geneva.
78. Yamaguchi H, Kobayashi GS, Takahashi H 1992. Recent Progress in Antifungal Chemotherapy, Marcel Dekker, New York.